High-dose Vitamin D Supplement for the Prevention of Acute Asthma-like Symptoms in Preschool Children (COPSACvitd)

High-dose Vitamin D Supplement for the Prevention of Acute Asthma-like Symptoms in Preschool Children - a Double-blind, Randomized, Controlled Trial

To investigate whether high-dose vitamin D supplementation may have a beneficial effect on secondary prevention in preschool children (1-5 years of age), with respiratory infections being the primary cause of acute exacerbations with asthma-like symptoms.

Study Overview

• Status: Recruiting
• Conditions: Asthma in Children
• Intervention / Treatment: Dietary supplement: Cholecalciferol D3; Other: Oral placebo suspension

Detailed Description

Asthma is a chronic inflammatory disease of the airways with a variable, reversible airway obstruction and hyper-reactivity in the airways. The disease results in intermittent episodes with asthma-like symptoms such as difficulty breathing with wheezing, dyspnoea, chest tightness and coughing. These episodes occur in connection with upper respiratory tract infections, physical activity and can be triggered by airborne allergens and by high particle load in the environment, including pollutants and tobacco smoke. The prevalence of asthma has more than doubled in the Western world, as well as in the societies that have embraced the Western world in recent decades. Currently, half of younger children experience asthma-like symptoms, 20% have recurrent symptoms, and by school age, 10% of children are diagnosed with asthma. Asthma and asthma-like symptoms are currently the primary cause of chronic use of medication and hospitalization of younger children, and have a major negative impact on children and their families, and also carry a significant socio-economic burden on society.

Preschool children who suffer from asthma and asthma-like symptoms have the highest rate of acute visits to a child's clinic compared to older children with asthma, and one in three requires real hospitalization in this regard. Most acute exacerbations with asthma-like symptoms in younger children are triggered by viral or bacterial upper respiratory tract infections, which are associated with poorer response to oral corticosteroids (OCS). OCS is currently one of the few options for the treatment of exacerbations in younger children (tertiary prevention). Preventive inhaled corticosteroid (ICS) as monotherapy or with the addition of oral leukotriene receptor antagonist (LTRA) is effective in achieving daily symptom control in preschool children with asthma and asthma-like symptoms (secondary prevention). However, up to 50% still experience acute exacerbations with asthma-like symptoms that require OCS treatment and / or hospitalization. At present, there are no official clinical guidelines describing step-up treatment with regard to to improve secondary prevention; in particular, there is a lack of intervention opportunities with regard to to reduce the high morbidity associated with acute asthma-like symptoms, which is therefore a major deficiency in the clinical management of this age group of vulnerable children.

Previous trials with vitamin D supplements A systematic review with 2016 meta-analysis, involving randomized controlled clinical trials (RCTs) of vitamin D supplementation for patients with asthma, showed that vitamin D supplementation significantly reduced the rate of acute exacerbations requiring OCS by 36% (relative rate (RR) 0.64, 658 adults / 22 preschool children) and acute visits to child reception or real hospitalizations with 61% (odds ratio (OR) 0.39, 664 adults / 277 school children / 22 preschool children). As there are few RCTs, and in these there is an under-representation of preschool children, great heterogeneity in vitamin D dose and concomitant ICS therapy, there was not enough power in the meta-analysis to examine subgroup differences, especially among younger children. It is therefore still unclear about patient characteristics such as age, baseline level of serum 25-hydroxyvitamin D (25OHD), genetic variations in vitamin D metabolism and / or treatment characteristics such as vitamin D treatment plan, including e.g. use of bolus versus no bolus, duration of treatment and form of administration influence the extent of the positive effect of vitamin D on acute asthma-like symptoms.

Pediatric RCTs have subsequently been performed, but none that have included preschool children. Currently, there are 7 published pediatric studies with relatively few included trial participants (n = 22-430). In the currently published RCTs, there is only one where the included children are of preschool age, which is a pilot study on the safety of vitamin D treatment of acute viral-induced asthma (DIVA). In the DIVA pilot study, 22 preschool children were randomized to an oral bolus of vitamin D of 100,000 international units (IU) (~ 250 μg) plus 400 IU / day (~ 10 μg / day) for 6 months or placebo. The treatment was safe and resulted in significantly increased serum 25OHD to a level> 75 nmol / L. However, the study did not have enough power to show a difference in acute doctor visits based on acute asthma-like symptoms. Apart from the so-called DIVA RCT (NCT03365687), there are no other registered RCTs regarding vitamin D supplementation for preschool children with acute asthma-like symptoms registered on clinicaltrials.gov. Therefore, there is a need for a study that includes preschoolers who have enough power to show whether vitamin D supplementation improves the secondary prevention of acute asthma-like symptoms by reducing the number of exacerbations and the need for OCS and / or hospitalization, independent of baseline serum 25OHD levels.

Potential mechanisms of vitamin D in acute asthma-like symptoms It is important to investigate the potential mechanisms of action of the possible protective role of vitamin D against acute asthma-like symptoms. These may be dependent on specific asthma phenotypes where vitamin D supplementation is more effective. A subgroup analysis from a 2017 meta-analysis of individual participant data from 25 RCTs showed that vitamin D supplementation significantly reduced the risk of acute upper respiratory tract infections by 40% (OR 0.60; 513 children) in a group of children aged 1- Sixteen years. This may suggest that vitamin D supplementation in particular may have a beneficial effect on secondary prevention in preschool children, with respiratory infections being the primary cause of acute exacerbations with asthma-like symptoms. Vitamin D coordinates the functions of the immune system both by inducing and by inhibiting inflammation as well as by modulating inflammatory and anti-inflammatory effects of the cells of the immune system. In most tissues exposed to infection or an allergen, the expression of the enzyme CYP27B1, which converts 25OHD to the active 1,25-dihydroxyvitamin D, is induced. The active 1,25-dihydroxyvitamin D binds to the vitamin D receptor (VDR), which regulates the transcription of many genes, including several associated with the smooth muscle cells of the bronchi, which may explain the observed association between serum 25OHD and airway reactivity. A study involving a similar patient group of infants with acute asthma symptoms found that gene expression was associated with vitamin D levels and was a predictor of later asthma, supporting the hypothesis that vitamin D plays a role in asthma at this age and that gene Expression can be an important biomarker for the effect of treatment. An immunomodulatory and synergistic effect of vitamin D on ICS treatment response and thus on airway inflammation may also be present, which is supported by observational studies.

Bone health status improves when serum 25OHD is> 75 nmol / L, which is equivalent to sufficient vitamin D status. However, the 25OHD threshold for optimal immunological, anti-inflammatory and respiratory function is unknown, but it is likely to be higher. In addition, genetic variation in the GC gene, which encodes vitamin D binding protein, plays a role in the level of 25OHD in the blood, which thus plays a role in the amount of vitamin D available in the target tissue. Research into vitamin D levels and the impact of immunological and inflammatory processes will increase the understanding of the mechanisms of action on acute asthma-like symptoms.

• Study Type: Interventional
• Enrollment (Estimated): 320
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Klaus Bønnelykke, MD, PhD; Phone Number: +4538677360; Email: kb@copsac.com
• Study Contact Backup: Name: Ulrik Ralfkiaer, MSc, PhD; Phone Number: +4538674164; Email: administration@dbac.dk

Study Locations

• Denmark
  • Gentofte, Denmark, 2820
    • Recruiting
    • University Hospital of Copenhagen
    • Contact: Ulrik Ralfkiaer, MSc, PhD; Phone Number: +4538674164; Email: administration@dbac.dk
    • Contact: Klaus Bønnelykke, MD, PhD; Phone Number: +45 38677360; Email: kb@copsac.com
    • Principal Investigator: Bo Chawes, MD, DMSc, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 year to 5 years (Child)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

The study population consists of children in the age group 1-5 years admitted to a pediatric ward, due to an acute episode with asthma-like symptoms. An acute asthma-like episode will be defined as annoying coughing, wheezing (wheezing or wheezing in connection with exhalation) and / or dyspnoea, which affects the child's well-being and requires hospitalization in a pediatric ward. Participation in the study requires that the child is in or has been in treatment with SABA, as monotherapy, or in combination with ICS, and possibly also in combination with LTRA in accordance with the Danish guidelines

Exclusion Criteria:

• The child is hospitalized with pneumonia
• The child's daily intake of vitamin D supplementation is> 400 IU / day (~ 10 μg / day).
• The child is given a combination of vitamin and dietary supplements containing vitamin D, thus the daily recommended dose is exceeded, as 2400 IU / day (~ 60 μg / day) is accepted for children aged 1-4 years, as everyone here is recommended to take 400 IU / day (~ 10 μg / day) by the Danish Health and Medicines Authority.
• The baby has been exclusively breastfed for the past 6 months.

• The child is malnourished

  • for children> 2 years of age whose age-specific BMI is less than the 3rd percentile.
  • for children <2 years, whose weight or height in relation to age is less than the 3rd percentile.
• The child is a newly arrived refugee or immigrant from regions with a high risk of rickets.
• The child has other chronic lung diseases.
• The child is diagnosed with other conditions such as chronic lung disease, impaired renal function, neurological or psychiatric disorders, congenital or documented acquired QT prolongation, clinically relevant bradycardia, cardiac arrhythmia or severe heart failure and / or hepatic impairment.
• The child is being treated with medication that alters calcium or vitamin D absorption / metabolism.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Vitamin D; Dietary supplement: 2000 IU Vitamin D3 daily dose (oral suspension) for one year.	Dietary supplement: Cholecalciferol D3; 2000 IU of Vitamin D provided as oral suspension for one year; Other Names: Vitamin D from Apovit, Denmark
Placebo Comparator: Placebo; Oral suspension with no active substance, identical to the active suspension for one year.	Other: Oral placebo suspension; Oral suspension with no active substance tasting like the active supplement.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of acute exacerbations	The primary objective of this double-blind, randomized, controlled clinical trial is to determine whether an oral daily dose of 2000 IU (~ 50 μg) of vitamin D administered for a total of 12 months versus placebo leads to: Decrease in the number of acute exacerbations with asthma-like symptoms that require treatment with OCS and / or lead to hospitalization / treatment at a pediatric clinic. This in children aged 1-5 years with a medical history with asthma-like symptoms, and is in or has received treatment with SABA as monotherapy, or in combination ICS and possibly also LTRA.	One year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Intervention with vitamin D versus placebo, time to first acute exacerbation	Change in time (days) to first acute exacerbation with asthma-like symptoms requiring OCS and / or hospitalization / treatment at a pediatric ward.	One year
Intervention with vitamin D versus placebo, duration of symptoms	Change of the duration (days) of symptoms / hospitalization.	One year
Intervention with vitamin D versus placebo, need for medical treatment	Change in the need for medical treatment during exacerbations, including SABA, short-acting anticholinergic inhalations (SAMA) and OCS.	One year
Intervention with vitamin D versus placebo, daily symptom burden	Change in the daily symptom burden between exacerbations.	One year
Intervention with vitamin D versus placebo, step-down of preventive treatment	Is the intervention associated with successful step-down of preventive medical asthma treatment.	One year
Safety profile of vitamin D intervention, calcium levels in blood	This study also aims to examine the safety profile of vitamin D intervention. This is done by examining group differences in the proportion of children with clinically significant: Hypo-calcemia (defined as total β-calcium below 2.20 mmol / l after correction for albumin); Hyper-calcemia (defined as total β-calcium above 2.55 mmol / l after correction for albumin)	One year
Safety profile of vitamin D intervention, calcium levels in urine	This study also aims to examine the safety profile of vitamin D intervention. This is done by examining group differences in the proportion of children with clinically significant: ● Hyper-calciuri as defined by Ca/creatinine-ratio in urine with a value above 1,0 mmol/mmol	One year
Safety profile of vitamin D intervention, serum 25OHD level	This study also aims to examine the safety profile of vitamin D intervention. This is done by examining group differences in the proportion of children with clinically significant serum 25OHD> 250 nmol / L.	One year
Safety profile of vitamin D intervention, Adverse Events	This study also aims to examine the safety profile of vitamin D intervention. This is done by examining group differences in the proportion of children with clinically significant incidence(s) of Adverse Events.	One year
Exploratory outcomes, baseline 25OHD	Analyzing baseline serum 25OHD (mol / L).	One year
Exploratory outcomes, genetic variation in VDR	Analyzing genetic variation of the Vitamin D Receptor gene (VDR).	One year
Exploratory outcomes, genetic variation in VDBP	Analyzing genetic variation of the Vitamin D Binding Protein gene (VDBP).	One year
Exploratory outcomes, expression levels of genes involved in the vitamin D metabolism	Analyzing expression in vitamin D metabolism related to VDR and Vitamin D binding protein (VDBP) and other relevant candidates in the vitamin D processing pathway.	One year
Exploratory outcomes, expression levels of asthma-related genes	Analyzing expression levels in known asthma-related genes, e.g. 17q21 and other relevant genes.	One year
Exploratory outcomes, genetic variation in asthma-related genes	Analyzing genetic variation in known asthma-related genes, e.g. 17q21 and other relevant genes.	One year
Exploratory outcomes, respiratory microbiome, conventional culture	Alpha- and beta Diversity of gut microbiota using conventional culturing assays.	One year
Exploratory outcomes, respiratory microbiome	Alpha- and beta diversity of gut microbiota using 16S rRNA sequencing and whole genome sequencing.	One year
Exploratory outcomes, respiratory virus detection	Alpha- and beta diversity of vira using targeted q-PCR.	One year
Exploratory outcomes, respiratory immune profile, blood eosinophilocyte counts	Measuring blood eosinophilocyte counts for inhalation allergens.	One year
Exploratory outcomes, respiratory immune profile, total-IgE	The study also aims to examine a wide range of exploratory outcomes to gain insight into the mechanisms of action behind the effects of vitamin D supplementation and possible effect modification, which can help identify children with particularly high effects of treatment, by analyzing the respiratory immune profile at the time of inclusion. Atopic status by measuring total-IgE for inhalation allergens.	One year
Exploratory outcomes, respiratory immune profile, specific-IgE	The study also aims to examine a wide range of exploratory outcomes to gain insight into the mechanisms of action behind the effects of vitamin D supplementation and possible effect modification, which can help identify children with particularly high effects of treatment, by analyzing the respiratory immune profile at the time of inclusion. ● Atopic status by measuring specific-IgE levels for inhalation allergens.	One year
Exploratory outcomes, atopic status, measuring blood eosinophilocyte counts	The study also aims to examine a wide range of exploratory outcomes to gain insight into the mechanisms of action behind the effects of vitamin D supplementation and possible effect modification, which can help identify children with particularly high effects of treatment, by analyzing the atopic status by measuring blood eosinophilocyte counts, for inhalation allergens.	One year
Exploratory outcomes, atopic status, total-IgE and specific-IgE levels	The study also aims to examine a wide range of exploratory outcomes to gain insight into the mechanisms of action behind the effects of vitamin D supplementation and possible effect modification, which can help identify children with particularly high effects of treatment, by analyzing the atopic status by measuring total-IgE and specific-IgE levels for inhalation allergens.	One year
COVID-19 risk and Vitamin-D	Does the vitamin-D intervention decrease the risk of COVID-19 infection, as determined by PCR test.	One year
COVID-19 symptom burden and Vitamin-D	Does D-vitamin supplementation change the symptom burden (in number of days) of COVID-19 infection, as determined by PCR test.	One year
COVID-19 infection length and Vitamin-D	Does D-vitamin supplementation change length (number of days) of COVID-19 infection, as determined by PCR test.	One year
Daycare absence	Does D-vitamin supplementation change number of days absent from daycare.	One year
Health economic benefits	Does D-vitamin supplementation change the number of days parents need to stay home to look after their children when they are absent from daycare.	One year

Collaborators and Investigators

• Sponsor: Copenhagen Studies on Asthma in Childhood
• Investigators: Principal Investigator: Bo Chawes, MD, DMSc, chawes@copsac.com

Publications and helpful links

General Publications

• Kyvsgaard JN, Ralfkiaer U, Folsgaard N, Jensen TM, Hesselberg LM, Schoos AM, Bonnelykke K, Bisgaard H, Stokholm J, Chawes B. Azithromycin and high-dose vitamin D for treatment and prevention of asthma-like episodes in hospitalised preschool children: study protocol for a combined double-blind randomised controlled trial. BMJ Open. 2022 Apr 13;12(4):e054762. doi: 10.1136/bmjopen-2021-054762.

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2022
• Primary Completion (Estimated): October 1, 2025
• Study Completion (Estimated): October 1, 2031

Study Registration Dates

• First Submitted: May 21, 2021
• First Submitted That Met QC Criteria: September 3, 2021
• First Posted (Actual): September 14, 2021

Study Record Updates

• Last Update Posted (Estimated): February 14, 2024
• Last Update Submitted That Met QC Criteria: February 13, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Keywords: Vitamin D; Infections; Wheeze
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Immune System Diseases; Lung Diseases; Hypersensitivity, Immediate; Bronchial Diseases; Lung Diseases, Obstructive; Respiratory Hypersensitivity; Hypersensitivity; Asthma; Physiological Effects of Drugs; Micronutrients; Vitamins; Bone Density Conservation Agents; Calcium-Regulating Hormones and Agents; Vitamin D; Cholecalciferol
• Other Study ID Numbers: H-20066827

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No